During a virtual Case-Based Roundtable, Daniel Landau and community oncologists discussed frontline treatment options for a 65-year-old man with newly diagnosed poor-risk metastatic clear cell renal cell carcinoma (ccRCC) and extensive bone involvement.
The panel agreed that the immediate priority in such patients is rapid tumor reduction to prevent complications such as spinal cord compression and paralysis. Combination therapy was universally favored, with single-agent treatment considered appropriate only when significant contraindications exist.
Most participants (60%) preferred a tyrosine kinase inhibitor (TKI) plus immune checkpoint inhibitor (ICI) regimen, citing the need for fast disease control and symptom relief. Axitinib plus pembrolizumab was highlighted as one potential approach. The remaining 40% favored dual immune checkpoint blockade with ipilimumab and nivolumab, particularly for patients who could wait several weeks for a response and might benefit from more durable long-term disease control.
The discussion reflected 2026 NCCN recommendations, which list both IO-TKI and IO-IO combinations as preferred first-line options for poor-risk metastatic ccRCC. Treatment selection ultimately depends on balancing the need for rapid tumor shrinkage against the potential for lasting remission and survival benefit.